Antifibrotics for COVID-19 Related Lung Fibrosis: Agents with Benefits?

Mayank Mishra; Girish Sindhwani

doi:10.5603/ARM.a2021.0023

You are currently on the new version of our website. Access the old version .

Advances in Respiratory Medicine is published by MDPI from Volume 90 Issue 4 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Via Medica.

Letter

30 April 2021

Antifibrotics for COVID-19 Related Lung Fibrosis: Agents with Benefits?

and

All India Institute of Medical Sciences, Rishikesh, India

Author to whom correspondence should be addressed.

Adv. Respir. Med.2021, 89(2), 231-233;https://doi.org/10.5603/ARM.a2021.0023

Version Notes

Order Reprints

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Coronavirus disease 2019 (COVID-19), caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an exponentially spreading pandemic with more than 36 million confirmed cases and over one million deaths worldwide, all within ten months of its first case in Wuhan, China [...]

Article Metrics

Citations

Article Access Statistics

Journal Statistics

Multiple requests from the same IP address are counted as one view.

EBUS-TBNA in Children: The Road Less Travelled

Long COVID-19: An Emerging Pandemic in Itself